# A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

> **NCT07650916** · PHASE3 · RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 564 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** CAB ULA
- **DRUG:** RPV ULA
- **DRUG:** CAB LA
- **DRUG:** RPV LA

## Key facts

- **NCT ID:** NCT07650916
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-25
- **Primary completion:** 2029-09-04
- **Final completion:** 2029-09-04
- **Target enrollment:** 564 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07650916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07650916, "A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07650916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*